LONDON (Alliance News) - Medical technology company ANGLE PLC Tuesday said the Medical University of Vienna has published test results in support of the use of the company's Parsotix cell separation system in detecting ovarian cancer.
The study conducted by the university found an analysis of seven RNA markets yielded 100% specificity, indicating no false positives were given. False positives are a key issue with existing techniques for cell separation, ANGLE said.
The sensitivity of the system to ovarian cancer was 80% at the point of diagnosis and 78% at relapse, compared with 24.5% sensitivity for other circulating tumour cell systems. The data also found a sensitivity of 71% for metastatic breast cancer patients, more than twice the level of sensitivity achieved using other CTC systems.
In addition, the university re-analysed the RNA information in order to improve the sensitivity further, this time using 30 RNA markers. The addition of the markers increased the sensitivity level to 92% on average across all cancers, and notably improved the ovarian cancer detection sensitivity rate to 100% for both point-of-diagnosis and relapse.
"The prospect of a simple blood test for cancer detection with such high sensitivity and specificity is extremely exciting. The results published today by Medical University of Vienna substantiate the early findings in ovarian cancer and extend the opportunity into breast cancer and other gynaecological cancers," said Andrew Newland, ANGLE's chief executive.
ANGLE shares were up 11% to 82.00 pence, one of the best performers in the AIM All-Share index.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Angle (AGL)